Investigation of Fenbendazole Solubility Using Particle Size Reduction Methods in the Presence of Soluplus®.

IF 5.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Amirhossein Karimi, Pedro Barea, Óscar Benito-Román, Beatriz Blanco, María Teresa Sanz, Clement L Higginbotham, John G Lyons
{"title":"Investigation of Fenbendazole Solubility Using Particle Size Reduction Methods in the Presence of Soluplus<sup>®</sup>.","authors":"Amirhossein Karimi, Pedro Barea, Óscar Benito-Román, Beatriz Blanco, María Teresa Sanz, Clement L Higginbotham, John G Lyons","doi":"10.3390/pharmaceutics17091163","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: Fenbendazole is a potential cancer treatment and a proven antiparasitic in veterinary applications. However, its poor water solubility limits its application. In this study, potential fenbendazole solubility enhancement was investigated through size reduction methods. The effect of the presence of Soluplus<sup>®</sup> on solubility was investigated as well. <b>Methods</b>: Solubility enhancement was explored using microfluidization and ultrasonication techniques. These techniques were applied to fenbendazole alone and in combination with Soluplus<sup>®</sup>. UV-Vis spectroscopy was used to determine solubility. Possible chemical reactions were checked using Fourier transform infrared spectroscopy (FT-IR). Differential scanning calorimetry (DSC) was conducted to analyze the physical structure and crystallinity of the samples. Scanning electron microscopy (SEM) was also utilized for characterization of the effect of the treated formulations and the size reduction method on morphology. The elements present in samples were identified with energy-dispersive X-ray spectroscopy (EDX) combined with SEM. A comparison of crystalline structure between the products was performed via X-ray powder diffraction (XRPD). Dynamic light scattering (DLS) was also used to measure the samples' average particle size at different stages. <b>Results</b>: Both ultrasonication and microfluidization led to marginal increases in the solubility of neat fenbendazole. In contrast, formulations processed in the presence of Soluplus<sup>®</sup> demonstrated a greater enhancement in solubility. However, solubility improvement was not retained in the dried samples. The post-drying samples, irrespective of the presence of Soluplus<sup>®</sup>, showed nearly the same solubility as neat fenbendazole. <b>Conclusions</b>: Size-reduction methods, particularly when combined with Soluplus<sup>®</sup>, improved the solubility of fenbendazole. However, drying appeared to reverse these gains, regardless of the method used.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 9","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17091163","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Fenbendazole is a potential cancer treatment and a proven antiparasitic in veterinary applications. However, its poor water solubility limits its application. In this study, potential fenbendazole solubility enhancement was investigated through size reduction methods. The effect of the presence of Soluplus® on solubility was investigated as well. Methods: Solubility enhancement was explored using microfluidization and ultrasonication techniques. These techniques were applied to fenbendazole alone and in combination with Soluplus®. UV-Vis spectroscopy was used to determine solubility. Possible chemical reactions were checked using Fourier transform infrared spectroscopy (FT-IR). Differential scanning calorimetry (DSC) was conducted to analyze the physical structure and crystallinity of the samples. Scanning electron microscopy (SEM) was also utilized for characterization of the effect of the treated formulations and the size reduction method on morphology. The elements present in samples were identified with energy-dispersive X-ray spectroscopy (EDX) combined with SEM. A comparison of crystalline structure between the products was performed via X-ray powder diffraction (XRPD). Dynamic light scattering (DLS) was also used to measure the samples' average particle size at different stages. Results: Both ultrasonication and microfluidization led to marginal increases in the solubility of neat fenbendazole. In contrast, formulations processed in the presence of Soluplus® demonstrated a greater enhancement in solubility. However, solubility improvement was not retained in the dried samples. The post-drying samples, irrespective of the presence of Soluplus®, showed nearly the same solubility as neat fenbendazole. Conclusions: Size-reduction methods, particularly when combined with Soluplus®, improved the solubility of fenbendazole. However, drying appeared to reverse these gains, regardless of the method used.

用粒径还原法研究芬苯达唑在Soluplus®存在下的溶解度。
背景/目的:芬苯达唑是一种潜在的癌症治疗药物,也是一种已被证实的抗寄生虫药。但其水溶性差,限制了其应用。在本研究中,研究了芬苯达唑的溶解度增强作用。还研究了Soluplus®的存在对溶解度的影响。方法:利用微流化技术和超声技术探讨提高溶解度的方法。这些技术分别用于芬苯达唑单用和与Soluplus®联合使用。紫外可见光谱法测定溶解度。利用傅里叶变换红外光谱(FT-IR)检查可能的化学反应。用差示扫描量热法(DSC)分析了样品的物理结构和结晶度。扫描电子显微镜(SEM)也用于表征处理后的配方和尺寸减小方法对形貌的影响。用能量色散x射线光谱(EDX)结合扫描电镜对样品中的元素进行了鉴定。通过x射线粉末衍射(XRPD)对产物的晶体结构进行了比较。动态光散射法(DLS)测量了不同阶段样品的平均粒径。结果:超声处理和微流化处理均能使纯芬苯达唑的溶解度略有提高。相比之下,在Soluplus®存在下加工的配方显示出更大的溶解度增强。然而,在干燥的样品中没有保留溶解度的改善。干燥后的样品,无论是否存在Soluplus®,其溶解度几乎与纯芬苯达唑相同。结论:缩小尺寸的方法,特别是与Soluplus®联合使用时,提高了芬苯达唑的溶解度。然而,无论使用何种方法,干燥似乎都会逆转这些增益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutics
Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍: Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications,  and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信